Stifel Nicolaus ups its target
from $8 to $11 on Santarus (SNTS +5%
) on the back of its highly successful Phase 3 results
for Rifamycin SV MMX in traveler’s diarrhea, and it's successful appeal against Par Pharmaceuticals (PRX
). The firm thinks that Zegerid will gain an extra $35M-$45M in annual sales as a result of the court decision, and it maintains a Buy rating on the stock.